欢迎访问西亚试剂!
西亚试剂banner
西亚试剂banner
西亚试剂banner

当前位置:首页 > 新闻中心

西亚试剂:miR-214 targets ATF4 to inhibit bone formation

发布时间:2025-10-03

miR-214 targets ATF4 to inhibit bone formation

Xiaogang Wang, Baosheng Guo, Qi Li, Jiang Peng, Zhijun Yang, Aiyuan Wang, Dong Li, Zhibo Hou, Ke Lv, Guanghan Kan, Hongqing Cao, Heng Wu, Jinping Song, Xiaohua Pan, Qiao Sun, Shukuan Ling, Yuheng Li, Mu Zhu, Pengfei Zhang, Songlin Peng, Xiaoqing Xie, Tao Tang, An Hong, Zhaoxiang Bian, Yanqiang Bai, Aiping Lu, Yinghui Li, Fuchu He, Ge Zhang & Yingxian Li

Emerging evidence indicates that microRNAs (s) have important roles in regulating osteogenic differentiation and bone formation. Thus far, no study has established the pathophysiological role for miRNAs identified in human osteoporotic bone specimens. Here we found that elevated miR-214 levels correlated with a lower degree of bone formation in bone specimens from aged patients with fractures. We also found that osteoblast-specific manipulation of miR-214 levels by miR-214 antagomir treatment in miR-214 transgenic, ovariectomized, or hindlimb-unloaded mice revealed an inhibitory role of miR-214 in regulating bone formation. Further, in vitro osteoblast activity and matrix mineralization were promoted by antagomir-214 and decreased by agomir-214, and miR-214 directly targeted ATF4 to inhibit osteoblast activity. These data suggest that miR-214 has a crucial role in suppressing bone formation and that miR-214 inhibition in osteoblasts may be a potential anabolic strategy for ameliorating osteoporosis.

 

上一篇:西亚试剂::“围观产生压力”有大脑生理基础
下一篇:高分子载体四氯化锡复合物催化剂
版权所有:山东西亚化学有限公司

鲁ICP备20015914号-4